Avaliação da concentração sérica de biomarcadores metabólicos e inflamatórios em pacientes obesos submetidos ao tratamento com balão intragástrico

• Ano de defesa: 2018
• Autor(a) principal: Guedes, Marcella Rodrigues
• Orientador(a): Klein, Márcia Regina Simas Torres
• Banca de defesa: Brandão, Andréa Araujo , Silva, Maria Inês Barreto , Rosa, Glorimar
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade do Estado do Rio de Janeiro
• Programa de Pós-Graduação: Programa de Pós-Graduação em Fisiopatologia Clínica e Experimental
• Departamento: Centro Biomédico::Faculdade de Ciências Médicas
• País: BR
• Palavras-chave em Português: Obesidade; Balão intragástrico; Adipocinas; Inflammation; Resistência à insulina; Balão gástrico; Resistencia à insulina
• Palavras-chave em Inglês: Intragastric balloon; Adipokines; Inflammation; Insulin resistance
• Área do conhecimento CNPq: CNPQ::CIENCIAS DA SAUDE::NUTRICAO
• Link de acesso: http://www.bdtd.uerj.br/handle/1/12720

Background: Obesity is associated with increased risk of morbidity and mortality through a number of mechanisms, including changes in serum levels of adipokines and proinflammatory cytokines. Although intragastric balloon (IGB) can be considered safe and effective, being a good alternative for weight loss, its effects on serum levels of these biomarkers are not known and have been evaluated in a few studies. To our knowledge no previous study has evaluated the effect of BIG on circulating levels of resistin, tumor necrosis factor-alpha (TNF-α) and interleukin (IL)-6. Aim: To evaluate the changes in serum levels of metabolic and inflammatory biomarkers in obese patients submitted to IGB treatment. Secondary objectives were to assess changes in body adiposity and quality of life. Methods: Prospective observational study involving patients with obesity grades I or II using BIG for 6 months. The patients were evaluated, on the day of insertion and withdrawal or adjustment of IGB, for: 1) total body adiposity: body mass index (BMI) and body fat (electrical bioimpedance; BIA); 2) central body adiposity: waist circumference, waist-to-hip ratio, waist-to-height ratio and neck circumference; 3) serum concentration of adiponectin, leptin, resistin, TNF-α, IL-6 and high sensitivity C-reative protein (hs-CRP); 4) glucose, insulin, total cholesterol and fractions and triglycerides; 5) quality of life through the SF-36 questionnaire; 6) food consumption by food frequency questionnaire; and 7) habitual physical activity by the Baecke questionnaire. Results: 42 patients were evaluated, 76% female, 37.6 ± 1.28 years old and BMI 35.15 ± 0.41 kg/m². There was a reduction of all anthropometric variables and of the percentage of fat mass by BIA. The weight loss was 15.88 ± 1.42%, and 73% of the patients achieved % total body weight loss &#8805; 10%, while the % excess weight loss was 56.07 ± 4.90%. There was a significant reduction (p<0.05) in leptin, hs-CRP, glucose, insulin, HOMA-IR and triglycerides, and an increase in the adiponectin / leptin ratio, but without significant changes in adiponectin, resistin, TNF- α and IL-6. Improvement of quality of life variables, reduction of energy intake and increase in total physical activity score were observed. Conclusion: The present study suggests that 6-month IGB treatment in obese patients is effective in reducing total and central body adiposity; serum levels of leptin , hs-CRP and triglycerides; and insulin resistance. Moreover, may increase adiponectin / leptin ratio and improve the quality of life.